Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
4.640
+0.260 (5.94%)
At close: Oct 8, 2026, 4:00 PM EDT
4.520
-0.120 (-2.59%)
After-hours: Oct 8, 2026, 7:30 PM EDT
Company Description
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States.
Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daron G. Evans M.B.A., M.S. | Chief Financial and Business Officer |
| Chris Milks | Vice President and Head of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 5, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 10-K | Annual Report |
| Sep 24, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 12, 2026 | SCHEDULE 13G/A | Filing |
| Aug 12, 2026 | SCHEDULE 13G | Filing |
| Jun 2, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |